CA125、HE4及ROMA指数在卵巢癌诊断方面的进展
Advances in CA125, HE4 and ROMA Index in the Diagnosis and Treatment of Ovarian Cancer
DOI: 10.12677/acm.2025.15123453, PDF,   
作者: 王馨悦：西安医学院第一附属医院妇科，陕西 西安；张少华*：西安医学院研究生工作部，陕西 西安
关键词: 卵巢癌；CA125；HE4；ROMA指数；肿瘤标志物；早期诊断；预后；Ovarian Cancer； CA125； HE4； ROMA Index； Tumor Markers； Early Diagnosis； Prognosis
摘要: 卵巢癌是目前死亡率最高的妇科恶性肿瘤，由于它的隐匿性临床亟需寻找有效的早期诊断方法。目前主要应用血清学标志物进行早期筛查，应用较广泛的包括血清糖类抗原125 (CA125)和人附睾分泌蛋白4 (HE4)。相较于单一指标检测，近年卵巢癌风险预测模型(ROMA)指数的出现提高了卵巢癌筛查的准确性与敏感性。此外血清学标志物在卵巢癌的病情监测和疗效评估方面也具有重要意义。但是现有的血清学标志物仍存在一些不足，如对卵巢癌早期诊断的特异性较低等。本文对CA125、HE4及ROMA指数在卵巢癌诊疗中的研究进展作一综述。
Abstract: Ovarian cancer is currently the gynecological malignancy with the highest mortality rate. Due to its insidious nature, there is an urgent clinical need to find effective early diagnostic methods. At present, serological markers are mainly used for early screening, among which carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4) are widely applied. Compared with single-index detection, the emergence of the Risk of Ovarian Malignancy Algorithm (ROMA) index in recent years has improved the accuracy and sensitivity of ovarian cancer screening. In addition, serological markers also play an important role in the monitoring of ovarian cancer progression and evaluation of therapeutic efficacy. However, existing serological markers still have some limitations, such as low specificity for early diagnosis of ovarian cancer. This article reviews the research progress of CA125, HE4 and ROMA index in the diagnosis and treatment of ovarian cancer.
文章引用：王馨悦, 张少华. CA125、HE4及ROMA指数在卵巢癌诊断方面的进展[J]. 临床医学进展, 2025, 15(12): 639-644. https://doi.org/10.12677/acm.2025.15123453

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] Armstrong, D.K., Alvarez, R.D., Backes, F.J., et al. (2022) NCCN Guidelines® Insights: Ovarian Cancer, Version 3. 2022. Journal of the National Comprehensive Cancer Network, 20, 972-980.
[3] Zhang, R., Siu, M.K.Y., Ngan, H.Y.S. and Chan, K.K.L. (2022) Molecular Biomarkers for the Early Detection of Ovarian Cancer. International Journal of Molecular Sciences, 23, Article 12041. [Google Scholar] [CrossRef] [PubMed]
[4] Bast, R.C., Feeney, M., Lazarus, H., Nadler, L.M., Colvin, R.B. and Knapp, R.C. (1981) Reactivity of a Monoclonal Antibody with Human Ovarian Carcinoma. Journal of Clinical Investigation, 68, 1331-1337. [Google Scholar] [CrossRef] [PubMed]
[5] Maeda, T., Inoue, M., Koshiba, S., Yabuki, T., Aoki, M., Nunokawa, E., et al. (2004) Solution Structure of the SEA Domain from the Murine Homologue of Ovarian Cancer Antigen CA125 (MUC16). Journal of Biological Chemistry, 279, 13174-13182. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, C., Weaver, S.D., Boonpattrawong, N., Schuster-Little, N., Patankar, M. and Whelan, R.J. (2024) A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-Read Sequencing. Cancer Research Communications, 4, 253-263. [Google Scholar] [CrossRef] [PubMed]
[7] Bast, R.C., Klug, T.L., John, E.S., Jenison, E., Niloff, J.M., Lazarus, H., et al. (1983) A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer. New England Journal of Medicine, 309, 883-887. [Google Scholar] [CrossRef] [PubMed]
[8] 张欣吴, 李晓江, 李洪君, 张蓉, 刘丽影. 盆腔良性肿物伴血清CA125水平升高的临床意义[J]. 中华妇产科杂志, 2005(3): 37-41.
[9] Kirchhoff, C., Habben, I., Ivell, R. and Krull, N. (1991) A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors1. Biology of Reproduction, 45, 350-357. [Google Scholar] [CrossRef] [PubMed]
[10] Schummer, M., Ng, W.V., Bumgarner, R.E., Nelson, P.S., Schummer, B., Bednarski, D.W., et al. (1999) Comparative Hybridization of an Array of 21 500 Ovarian cDNAs for the Discovery of Genes Overexpressed in Ovarian Carcinomas. Gene, 238, 375-385. [Google Scholar] [CrossRef] [PubMed]
[11] Hellström, I., Raycraft, J., Hayden-Ledbetter, M., et al. (2003) The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma. Cancer Research, 63, 3695-3700.
[12] Galgano, M.T., Hampton, G.M. and Frierson, H.F. (2006) Comprehensive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853. [Google Scholar] [CrossRef] [PubMed]
[13] Anastasi, E., Farina, A., Granato, T., Colaiacovo, F., Pucci, B., Tartaglione, S., et al. (2023) Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis. International Journal of Molecular Sciences, 24, Article 10479. [Google Scholar] [CrossRef] [PubMed]
[14] Granato, T., Porpora, M.G., Longo, F., Angeloni, A., Manganaro, L. and Anastasi, E. (2015) HE4 in the Differential Diagnosis of Ovarian Masses. Clinica Chimica Acta, 446, 147-155. [Google Scholar] [CrossRef] [PubMed]
[15] Anastasi, E., Giovanna Marchei, G., Viggiani, V., Gennarini, G., Frati, L. and Reale, M.G. (2010) HE4: A New Potential Early Biomarker for the Recurrence of Ovarian Cancer. Tumor Biology, 31, 113-119. [Google Scholar] [CrossRef] [PubMed]
[16] Suri, A., Perumal, V., Ammalli, P., Suryan, V. and Bansal, S.K. (2021) Diagnostic Measures Comparison for Ovarian Malignancy Risk in Epithelial Ovarian Cancer Patients: A Meta-Analysis. Scientific Reports, 11, Article No. 17308. [Google Scholar] [CrossRef] [PubMed]
[17] 李凤梅. 血清MALAT1、ENA-78、HE4表达情况与子宫内膜异位症进展的关系研究[J]. 实用中西医结合临床, 2021, 21(6): 108-111.
[18] Micu, R., Gaia-Oltean, A.M.I., Budişan, L., Braicu, C., Irimie, A. and Berindan-Neagoe, I. (2023) The Added Value of CA125, HE4, and CA72-4 as Markers for Ovarian Endometriosis Diagnosis. Romanian Journal of Morphology and Embryology, 64, 159-164. [Google Scholar] [CrossRef] [PubMed]
[19] Han, Y., Jiang, L., Liu, K., Ouyang, L. and Li, Y. (2021) Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review. Frontiers in Oncology, 11, Article 703949. [Google Scholar] [CrossRef] [PubMed]
[20] Plotti, F., Terranova, C., Guzzo, F., De Cicco Nardone, C., Luvero, D., Bartolone, M., et al. (2021) Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study. Biomedicines, 9, Article 55. [Google Scholar] [CrossRef] [PubMed]
[21] Cao, H., You, D., Lan, Z., Ye, H., Hou, M. and Xi, M. (2018) Prognostic Value of Serum and Tissue HE4 Expression in Ovarian Cancer: A Systematic Review with Meta-Analysis of 90 Studies. Expert Review of Molecular Diagnostics, 18, 371-383. [Google Scholar] [CrossRef] [PubMed]
[22] Moore, R.G., McMeekin, D.S., Brown, A.K., DiSilvestro, P., Miller, M.C., Allard, W.J., et al. (2009) A Novel Multiple Marker Bioassay Utilizing HE4 and CA125 for the Prediction of Ovarian Cancer in Patients with a Pelvic Mass. Gynecologic Oncology, 112, 40-46. [Google Scholar] [CrossRef] [PubMed]
[23] Yue, X., Yue, Z., Wang, Y., Dong, Z., Yang, H. and Yue, S. (2022) Value of the Copenhagen Index in the Diagnosis of Malignant Adnexal Tumors: A Meta‐analysis. International Journal of Gynecology & Obstetrics, 160, 506-515. [Google Scholar] [CrossRef] [PubMed]
[24] 孟靖涵, 何秀丽. IOTASR与CA125、HE4、ROMA、RMI1、GI-RADS对卵巢良恶性肿瘤的诊断价值比较[J]. 中国实用妇科与产科杂志, 2021, 37(1): 100-104.
[25] Hada, A., Han, L., Chen, Y., Hu, Q., Yuan, Y. and Liu, L. (2020) Comparison of the Predictive Performance of Risk of Malignancy Indexes 1-4, HE4 and Risk of Malignancy Algorithm in the Triage of Adnexal Masses. Journal of Ovarian Research, 13, Article No. 46. [Google Scholar] [CrossRef] [PubMed]
[26] Olsen, M., Lof, P., Stiekema, A., van den Broek, D., Wilthagen, E.A., Bossuyt, P.M., et al. (2021) The Diagnostic Accuracy of Human Epididymis Protein 4 (HE4) for Discriminating between Benign and Malignant Pelvic Masses: A Systematic Review and Meta‐Analysis. Acta Obstetricia et Gynecologica Scandinavica, 100, 1788-1799. [Google Scholar] [CrossRef] [PubMed]
[27] 金昌浩, 王洋. ROMA指数联合D-二聚体对卵巢癌的诊断价值[J]. 中国老年学杂志, 2024, 44(4): 806-808.
[28] Irajizad, E., Han, C.Y., Celestino, J., Wu, R., Murage, E., Spencer, R., et al. (2022) A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses. Clinical Cancer Research, 28, 4669-4676. [Google Scholar] [CrossRef] [PubMed]

为你推荐